MIM
GTHX

Macroview Investment Management’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History

Macroview Investment Management’s Portfolio GTHX Stock Details GTHX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-819
Closed -$10K – 528
2022
Q3 		$10K Buy
+819
New +$9.36K 0.02% 228

Other funds holding GTHX

Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Macroview Investment Management's GTHX Position: Q4 2022 in Review

Macroview Investment Management sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q4 2022, closing a stake of 819 shares — an estimated $10K sold.

Macroview Investment Management first reported a position in GTHX in Q3 2022 and held it in 1 quarter. The position peaked at $10K in Q3 2022. 116 funds tracked by Wall St. Rank hold GTHX as of Q4 2022.

  • Macroview Investment Management reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • Macroview Investment Management sold 819 G1 Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $10K.
  • Macroview Investment Management first reported a position in G1 Therapeutics, Inc. Common Stock in Q3 2022 and held it in 1 quarter.
  • Macroview Investment Management's G1 Therapeutics, Inc. Common Stock position peaked at $10K in Q3 2022.
  • 116 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q4 2022.

Based on Macroview Investment Management's 13F filing for Q4 2022, filed 11 Jan 2023.